EA200800710A1 - Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора - Google Patents

Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора

Info

Publication number
EA200800710A1
EA200800710A1 EA200800710A EA200800710A EA200800710A1 EA 200800710 A1 EA200800710 A1 EA 200800710A1 EA 200800710 A EA200800710 A EA 200800710A EA 200800710 A EA200800710 A EA 200800710A EA 200800710 A1 EA200800710 A1 EA 200800710A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
androgen receptor
treating
ras
burns
Prior art date
Application number
EA200800710A
Other languages
English (en)
Inventor
Джеймс Т. Долтон
Дуэйн Д. Миллер
Original Assignee
Юниверсити Оф Теннесси Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Теннесси Рисерч Фаундейшн filed Critical Юниверсити Оф Теннесси Рисерч Фаундейшн
Publication of EA200800710A1 publication Critical patent/EA200800710A1/ru
Priority to EA201101574A priority Critical patent/EA019849B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/32—Tin compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Abstract

Данное изобретение обеспечивает: 1) способ лечения субъекта, страдающего от или предрасположенного к заболеванию почек или нарушению функции почек; 2) способ лечения субъекта, страдающего от раны или уменьшение частоты, или смягчение силы раны у субъекта; 3) способ лечения субъекта, страдающего от ожога или уменьшение частоты, или смягчение силы ожога у субъекта, содержащий стадию введения упомянутому субъекту соединения селективного модулятора андрогенового рецептора (SARM); 4) способ лечения субъекта, страдающего от повреждения спинного мозга, введением субъекту селективного модулятора андрогенового рецептора (SARM) и/или аналога, производного, изомера, метаболита, фармацевтически приемлемой соли, фармацевтического продукта, гидрата, N-оксила, пролекарства, полиморфа, примеси или кристаллической формы упомянутого SARM соединения или их любой комбинации.
EA200800710A 2005-08-31 2006-08-28 Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора EA200800710A1 (ru)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201101574A EA019849B1 (ru) 2006-08-28 2011-11-25 Способ лечения, подавления, ингибирования или уменьшения инцидентов симптомов, ассоциированных с почечным заболеванием: гипогонадизма и непроизвольной потери веса

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71239005P 2005-08-31 2005-08-31
PCT/US2006/033490 WO2007027582A2 (en) 2005-08-31 2006-08-28 Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
EA200800710A1 true EA200800710A1 (ru) 2008-06-30

Family

ID=37809404

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800710A EA200800710A1 (ru) 2005-08-31 2006-08-28 Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора

Country Status (14)

Country Link
US (1) US20070066568A1 (ru)
EP (2) EP1931199A4 (ru)
JP (1) JP2009506119A (ru)
KR (1) KR101388087B1 (ru)
CN (1) CN101299920A (ru)
AU (1) AU2006285026B2 (ru)
BR (1) BRPI0617117A2 (ru)
CA (1) CA2621189A1 (ru)
DK (1) DK2425715T3 (ru)
EA (1) EA200800710A1 (ru)
ES (1) ES2453981T3 (ru)
IL (1) IL189843A0 (ru)
PT (1) PT2425715E (ru)
WO (1) WO2007027582A2 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
EP1562594A4 (en) * 2002-10-15 2008-12-17 Univ Tennessee Res Foundation SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH METHYLENE BRIDGES AND METHOD OF USE THEREOF
CA2501874A1 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US8080682B2 (en) 2006-08-24 2011-12-20 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
PL2205552T3 (pl) * 2007-09-11 2018-07-31 Gtx, Inc. Krystaliczny polimorf selektywnych modulatorów receptora androgenowego (R) lub (S)-N-(4-cyjano-3-(trifluorometylo)fenylo)-3-(4-cyjanofenoksy)-2-hydroksy-2-metylopropanamidu
US7968603B2 (en) * 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8377886B2 (en) * 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
JP5604807B2 (ja) * 2008-05-21 2014-10-15 日産自動車株式会社 燃料ホース
BRPI1013903B1 (pt) 2009-04-30 2020-03-03 Midwestern University Uso de um agente adrenérgico e um antagonista de endotelina-A, composição e uso de centaquina
KR20120115380A (ko) 2010-01-11 2012-10-17 지티엑스, 인코포레이티드 마이봄선 기능 장애의 치료 방법
US9511077B2 (en) * 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) * 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
KR102122941B1 (ko) 2012-07-13 2020-06-15 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR102138526B1 (ko) * 2014-01-14 2020-07-28 엘지전자 주식회사 퀵 컨트롤 메뉴를 제공하는 디지털 디바이스 및 그 제어 방법
US10064874B2 (en) 2014-10-22 2018-09-04 Havah Therapeutics Pty Ltd. Methods of reducing mammographic breast density and/or breast cancer risk
CA3002562A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CN112469474A (zh) * 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化
CN114599369A (zh) 2019-06-03 2022-06-07 哈瓦赫治疗有限公司 用于递送雄激素剂和芳香酶抑制剂的药物制剂和系统以及使用方法
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN116981451A (zh) * 2021-01-15 2023-10-31 田纳西大学研究基金会 用于治疗乳腺癌的药物组合物及其使用方法
WO2022271951A1 (en) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
WO1989007111A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US5179080A (en) * 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CA2336714A1 (en) 1998-07-06 2000-01-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
AU8523001A (en) * 2000-08-24 2002-03-04 Gtx Inc Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
GEP20063984B (en) * 2001-12-06 2006-12-11 Gtx Inc Use of selective androgen receptor modulators for treating muscle wasting
EA013818B1 (ru) * 2002-02-28 2010-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Полизамещённые селективные модуляторы рецептора андрогенов и способы их применения
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
JP2006505563A (ja) * 2002-10-15 2006-02-16 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体調節剤による肥満治療
US8080682B2 (en) * 2006-08-24 2011-12-20 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
CA2512049A1 (en) * 2002-12-30 2004-07-22 Purdue Research Foundation Method of treatment for central nervous system injury
TW200530181A (en) * 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
EP1753417B1 (en) * 2004-06-07 2012-04-04 University Of Tennessee Research Foundation A selective androgen receptor modulator and medical uses thereof

Also Published As

Publication number Publication date
EP1931199A4 (en) 2009-07-29
JP2009506119A (ja) 2009-02-12
IL189843A0 (en) 2008-08-07
EP2425715A1 (en) 2012-03-07
EP1931199A2 (en) 2008-06-18
KR101388087B1 (ko) 2014-04-25
WO2007027582A3 (en) 2007-10-25
US20070066568A1 (en) 2007-03-22
DK2425715T3 (da) 2014-04-28
PT2425715E (pt) 2014-04-14
WO2007027582A2 (en) 2007-03-08
AU2006285026A1 (en) 2007-03-08
BRPI0617117A2 (pt) 2011-07-12
KR20080045726A (ko) 2008-05-23
CA2621189A1 (en) 2007-03-08
AU2006285026B2 (en) 2012-08-09
CN101299920A (zh) 2008-11-05
ES2453981T3 (es) 2014-04-09
EP2425715B1 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
EA200800710A1 (ru) Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора
EA201391319A1 (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
EA200800147A1 (ru) Способ получения олмесартан медоксомила
EA201370184A1 (ru) Гетероарильные производные
EA201101507A1 (ru) Способы лечения солидных опухолей
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
MY133624A (en) Thio-substituted indole acetic acid derivatives for the treatment of respiratory disease
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
EA201071298A1 (ru) Соединение 3-аминокарбазола, фармацевтическая композиция, его содержащая, и способ их получения
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
MX368368B (es) Compuestos de indol e indazol como un inhibidor de necrosis celular.
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
MY145694A (en) Spiroheterocyclic compounds and their uses as therapeutic agents
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007025005A3 (en) Sustained release formulations of nalbuphine
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
EA201001524A1 (ru) Ингибиторы дезацетилазы в, основанные на гидроксамате
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
TW200736251A (en) Aryl-isoxazol-4-yl-imidazole derivatives
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств